Gene therapy for rat renal anemia with implantation of erythropoietin-transgenic myoblasts

Science in China. Series C, Life Sciences
Y LiuF He

Abstract

To investigate whether an erythropoietin (EPO) gene-based therapy could serve as an alternative to the repeated injection of rhEPO in treatment to renal anemia, the genetically modified myoblasts of rats, named Myo/ EPO, were implanted through intramuscular injection to model rats with renal anemia. The hemoglobin (Hb) and hematocrit (HCT) of the rats increased from (92.5 +/-3.0) g/L and 0.29+/-0.04 to the peak values of (103.8 +/-5.0) g/L and 0. 32 +/-0. 04 respectively 14 d after implantation, and sustained the pre-implantation level for 90 d. Otherwise, the control rats implanted with Myo/X, which carried the parent retroviral vector, gradually became severe in anemia. The PCR detection for hEPO cDNA in the rat muscle adjacent to injection sites indicated that the Myo/EPO cells survived for a long period in the muscle of rats. The results primarily demonstrate that myoblast gene transfer of EPO is effective for the treatment of rat renal anemia.

References

Jul 1, 1990·British Journal of Haematology·O CynshiK Hirashima
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·W R OsborneA W Clowes
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·N NaffakhY Beuzard
Nov 1, 1994·Human Gene Therapy·Y HamamoriL Kedes
Aug 1, 1993·Trends in Genetics : TIG·H M BlauG K Pavlath

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.